Blog

Soleno Therapeutics is anxiously awaiting FDA approval on its extended-release formulation of diazoxide choline (DCCR), which is indicated for treating Prader-Willis syndrome (PWS). Soleno’s drug has already received breakthroughdesignation status from FDA, as well as orphan drug designation.  Together, that suggests that if Soleno’s drug is approved this month, it will receive FDA-approved exclusivity for seven years.  Yet, after that, which patents does Soleno have that it can use to delay entry of generics?